The author reported a rare case of 66-year-old man presenting with cutaneous lesion with a red line spreading along the venous path three days after the first cycle of docetaxel in advanced stage lung cancer. The examination revealed unilateral wellde fined linear, non- blanchable erythematous to violaceous plaques along the superficial venous network of the right foot and then progressed to the right leg and extended above the right knee. A lesional skin biopsy was done and histopathological findings showed superficial interface dermatitis consistent with supravenous serpentine dermatitis. He was treated with topical betamethasone valerate (0.1%) cream twice daily for one week. The skin lesion improved but he still had residual hyperpigmented skin along the superficial venous network. However, there were some limitations of other chemotherapeutic agents, including pemetrexate and targeted therapy, such as the cost, the second cycle of docetaxel was used with more dilution, the extended time of intravenous transfusion, and the saline infusion before and after chemotherapy. This cutaneous side effect did not occur again. The present case report showed the interruption of docetaxel is not indicted when this reaction happens because it is self-limited. Prevention of this eruption can be achieved by extending the time of drug transfusion, and increasing the dilution of chemotherapy and saline infusion before and after chemotherapy.

Keywords: Docetaxel, Supravenous serpentine dermatitis, Lung cancer, Superficial interface dermatitis